Market
Which therapeutic area will AlphaFold AI target first in clinical trials by end of 2025?
2
Google DeepMind•Demis Hassabis•AlphaFold AI•Hassabis•Isomorphic Labs•World Economic Forum•Davos•Eli Lilly•Novartis
Resolution / Starting Odds
Cancer • 25%
Heart Disease • 25%
Neurodegenerative Diseases • 25%
Other • 25%
Official announcements from Google DeepMind or Isomorphic Labs, clinical trial registries
Story
Google DeepMind's AlphaFold AI Drugs to Enter Clinical Trials by Year-End, Led by Nobel Prize Winner
Jan 24, 2025, 05:54 PM
Google DeepMind's CEO, Demis Hassabis, has announced that the company's AI-designed drugs, developed using the AlphaFold AI technology, are expected to enter clinical trials by the end of the year. These drugs target major therapeutic areas including cancer, heart disease, and neurodegenerative diseases. Hassabis, a Nobel Prize winner and leader of Isomorphic Labs, a Google DeepMind spinoff, stated that the AI technology aims to reduce the drug discovery process from a decade to weeks or months. The announcement was made during a panel at the World Economic Forum in Davos. Isomorphic Labs has already established strategic research collaborations with pharmaceutical giants Eli Lilly and Novartis to further this initiative.
View original story
Similar markets
Viral infections • 25%
Cancer treatment • 25%
Autoimmune diseases • 25%
Bacterial infections • 25%
Neurological disorders • 25%
Cancer • 25%
Other • 25%
Infectious diseases • 25%
Partnership with NGO • 25%
No further development • 25%
Phase 1 Clinical Trials • 25%
Licensing Agreement • 25%
Africa • 25%
South America • 25%
Southeast Asia • 25%
Other • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Pfizer • 25%
Hypertension • 25%
Diabetes • 25%
Chronic Obstructive Pulmonary Disease (COPD) • 25%
Cancer • 25%
Pfizer • 25%
Roche • 25%
Other • 25%
Johnson & Johnson • 25%
Organ regeneration • 25%
Neural enhancement • 25%
Genetic modification • 25%
Other • 25%
No New Collaboration • 25%
Retro Biosciences • 25%
New Partner • 25%
Existing Tech Company • 25%